**Supplementary Table S1**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Supplementary Table S1.** | | | | |
| **A)** DSC of nanoparticulate formulations and raw materials. | | | | |
| **Sample** | **T1 (°C)** | **T2 (°C)** | | **T3 (°C)** |
| PLGA | 51 | 246 | | -- |
| PVA | 70.9 | 195 | | -- |
| Plx188 | 56 | -- | | -- |
| Rapamycin | 186 | 197 | |  |
| PLGA NPs | 54 | 156 | | 166 |
| Rap-PLGA NPs | 53 | 155 | | 165 |
|  | | | | |
| **B)** TGA of nanoparticulate formulations and excipients. | | | | |
| **Sample** | **T1 (°C)** | | **T2 (°C)** | |
| PLGA | 195-349 | | -- | |
| PVA | 257-365 | | 380-468 | |
| Plx188 | 250-363 | | -- | |
| Rapamycin | 196-460 | | 220-250 | |
| PLGA NPs | 216-329 | | -- | |
| Rap-PLGA NPs | 216-326 | | -- | |